C Handforth1, A Clegg2, C Young3, S Simpkins2, M T Seymour3, P J Selby3, J Young2. 1. St James' Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds. Electronic address: ugm4ch@leeds.ac.uk. 2. Academic Unit of Elderly Care and Rehabilitation, University of Leeds, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK. 3. St James' Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds.
Abstract
BACKGROUND: Frailty is a state of vulnerability to poor resolution of homeostasis following a stressor event, such as chemotherapy or cancer surgery. Better knowledge of the epidemiology of frailty could help drive a global cancer care strategy for older people. The aim of this review was to establish the prevalence and outcomes of frailty and pre-frailty in older cancer patients. METHODS: Observational studies that reported data on the prevalence and/or outcomes of frailty in older cancer patients with any stage of solid or haematological malignancy were considered. We searched Medline, CINAHL, Cochrane Library, EMBASE, Web of Science, Allied and Complementary medicine, Psychinfo and ProQuest (1 January 1996 to 30 June 2013). The primary outcomes were prevalence of frailty, treatment-related side-effects, unplanned hospitalization and mortality. Risk of bias was assessed using the Newcastle-Ottawa checklist. RESULTS: Data from 20 studies evaluating 2916 participants are included. The median reported prevalence of frailty and pre-frailty was 42% (range 6%-86%) and 43% (range 13%-79%), respectively. A median of 32% (range 11%-78%) of patients were classified as fit. Frailty was independently associated with increased all-cause mortality [adjusted 5-year hazard ratio (HR) 1.87, 95% confidence interval (CI) 1.36-2.57]. There was evidence of increased risk of postoperative mortality for both frailty (adjusted 30-day HR 2.67, 95% CI 1.08-6.62) and pre-frailty (adjusted HR 2.33, 95% CI 1.20-4.52). Treatment complications were more frequent in those with frailty, including intolerance to cancer treatment (adjusted odds ratio 4.86, 95% CI 2.19-10.78) and postoperative complications (adjusted 30-day HR 3.19, 95% CI 1.68-6.04). CONCLUSIONS: More than half of older cancer patients have pre-frailty or frailty and these patients are at increased risk of chemotherapy intolerance, postoperative complications and mortality. The findings of this review support routine assessment of frailty in older cancer patients to guide treatment decisions, and the development of multidisciplinary geriatric oncology services.
BACKGROUND: Frailty is a state of vulnerability to poor resolution of homeostasis following a stressor event, such as chemotherapy or cancer surgery. Better knowledge of the epidemiology of frailty could help drive a global cancer care strategy for older people. The aim of this review was to establish the prevalence and outcomes of frailty and pre-frailty in older cancerpatients. METHODS: Observational studies that reported data on the prevalence and/or outcomes of frailty in older cancerpatients with any stage of solid or haematological malignancy were considered. We searched Medline, CINAHL, Cochrane Library, EMBASE, Web of Science, Allied and Complementary medicine, Psychinfo and ProQuest (1 January 1996 to 30 June 2013). The primary outcomes were prevalence of frailty, treatment-related side-effects, unplanned hospitalization and mortality. Risk of bias was assessed using the Newcastle-Ottawa checklist. RESULTS: Data from 20 studies evaluating 2916 participants are included. The median reported prevalence of frailty and pre-frailty was 42% (range 6%-86%) and 43% (range 13%-79%), respectively. A median of 32% (range 11%-78%) of patients were classified as fit. Frailty was independently associated with increased all-cause mortality [adjusted 5-year hazard ratio (HR) 1.87, 95% confidence interval (CI) 1.36-2.57]. There was evidence of increased risk of postoperative mortality for both frailty (adjusted 30-day HR 2.67, 95% CI 1.08-6.62) and pre-frailty (adjusted HR 2.33, 95% CI 1.20-4.52). Treatment complications were more frequent in those with frailty, including intolerance to cancer treatment (adjusted odds ratio 4.86, 95% CI 2.19-10.78) and postoperative complications (adjusted 30-day HR 3.19, 95% CI 1.68-6.04). CONCLUSIONS: More than half of older cancerpatients have pre-frailty or frailty and these patients are at increased risk of chemotherapy intolerance, postoperative complications and mortality. The findings of this review support routine assessment of frailty in older cancerpatients to guide treatment decisions, and the development of multidisciplinary geriatric oncology services.
Authors: Casey M Hay; Heidi S Donovan; Grace B Campbell; Sarah E Taylor; Li Wang; Madeleine Courtney-Brooks Journal: Gynecol Oncol Date: 2018-11-28 Impact factor: 5.482
Authors: Maude Trepanier; Tiffany Paradis; Araz Kouyoumdjian; Teodora Dumitra; Patrick Charlebois; Barry S Stein; A Sender Liberman; Kevin Schwartzman; Franco Carli; Gerald M Fried; Liane S Feldman; Lawrence Lee Journal: J Gastrointest Surg Date: 2019-07-31 Impact factor: 3.452
Authors: Elisabeth J M Driessen; Judith G M van Loon; Huub A Maas; Anne-Marie C Dingemans; Maryska L G Janssen-Heijnen Journal: Lung Date: 2018-04-12 Impact factor: 2.584
Authors: Daniel Jones; Erica di Martino; Nathaniel L Hatton; Claire Surr; Niek de Wit; Richard D Neal Journal: Br J Gen Pract Date: 2020-06-25 Impact factor: 5.386
Authors: Caitlin W Hicks; Jeffrey J Tosoian; Rebecca Craig-Schapiro; Vicente Valero; John L Cameron; Frederic E Eckhauser; Kenzo Hirose; Martin A Makary; Timothy M Pawlik; Nita Ahuja; Matthew J Weiss; Christopher L Wolfgang Journal: Am J Surg Date: 2015-06-29 Impact factor: 2.565
Authors: Harvey Jay Cohen; David Smith; Can-Lan Sun; William Tew; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Julie Filo; Vani Katheria; Arti Hurria Journal: Cancer Date: 2016-08-16 Impact factor: 6.860